Abstract
Background: Women with a germline mutation in one of the MMR genes MLH1, MSH2 or MSH6 reportedly have 4e12% lifetime risk of ovarian cancer, but there is limited knowledge on survival. Prophylactic bilateral salpingooophorectomy (PBSO) has been suggested for preventing this condition. Aim: The purpose of this retrospective multicentre study was to describe survival in carriers of pathogenic mutations in one of the MMR genes, and who had contracted ovarian cancer. Methods: Women who had ovarian cancer, and who tested positive for or were obligate carriers of an MMR mutation, were included from 11 European centres for hereditary cancer. Most women had not attended for gynaecological screening. Crude and disease specific survival was calculated by the KaplaneMeier algorithm. Results: Among the 144 women included, 81.5% had FIGO stage 1 or 2 at diagnosis. 10 year ovarian cancer specific survival independent of staging was 80.6%, compared to less than 40% that is reported both in population based series and in BRCA mutation carriers. Disease specific 30 year survival for ovarian cancer was 71.5%, and for all hereditary non-polyposis colon cancer (HNPCC)/Lynch syndrome related cancers including ovarian cancer it was 47.3%. Conclusions: In the series examined, infiltrating ovarian cancer in Lynch syndrome had a better prognosis than infiltrating ovarian cancer in BRCA1/2 mutation carriers or in the general population. Lifetime risk of ovarian cancer of about 10% and a risk of dying of ovarian cancer of 20% gave a lifetime risk of dying of ovarian cancer of about 2% in female MMR mutation carriers.
| Original language | English |
|---|---|
| Pages (from-to) | 99-102 |
| Number of pages | 4 |
| Journal | Journal of Medical Genetics |
| Volume | 47 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2010 |
Fingerprint
ASJC Scopus subject areas
- Genetics
- Genetics(clinical)
Cite this
Survival in women with MMR mutations and ovarian cancer : A multicentre study in Lynch syndrome kindreds. / Grindedal, Eli Marie; Renkonen-Sinisalo, Laura; Vasen, Hans; Evans, Gareth; Sala, Paola; Blanco, Ignacio; Gronwald, Jacek; Apold, Jaran; Eccles, Diana M.; Sánchez, Ángel Alonso; Sampson, Julian; Järvinen, Heikki J.; Bertario, Lucio; Crawford, Gillian C.; Stormorken, Astrid Tenden; Maehle, Lovise; Moller, Pal.
In: Journal of Medical Genetics, Vol. 47, No. 2, 02.2010, p. 99-102.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Survival in women with MMR mutations and ovarian cancer
T2 - A multicentre study in Lynch syndrome kindreds
AU - Grindedal, Eli Marie
AU - Renkonen-Sinisalo, Laura
AU - Vasen, Hans
AU - Evans, Gareth
AU - Sala, Paola
AU - Blanco, Ignacio
AU - Gronwald, Jacek
AU - Apold, Jaran
AU - Eccles, Diana M.
AU - Sánchez, Ángel Alonso
AU - Sampson, Julian
AU - Järvinen, Heikki J.
AU - Bertario, Lucio
AU - Crawford, Gillian C.
AU - Stormorken, Astrid Tenden
AU - Maehle, Lovise
AU - Moller, Pal
PY - 2010/2
Y1 - 2010/2
N2 - Background: Women with a germline mutation in one of the MMR genes MLH1, MSH2 or MSH6 reportedly have 4e12% lifetime risk of ovarian cancer, but there is limited knowledge on survival. Prophylactic bilateral salpingooophorectomy (PBSO) has been suggested for preventing this condition. Aim: The purpose of this retrospective multicentre study was to describe survival in carriers of pathogenic mutations in one of the MMR genes, and who had contracted ovarian cancer. Methods: Women who had ovarian cancer, and who tested positive for or were obligate carriers of an MMR mutation, were included from 11 European centres for hereditary cancer. Most women had not attended for gynaecological screening. Crude and disease specific survival was calculated by the KaplaneMeier algorithm. Results: Among the 144 women included, 81.5% had FIGO stage 1 or 2 at diagnosis. 10 year ovarian cancer specific survival independent of staging was 80.6%, compared to less than 40% that is reported both in population based series and in BRCA mutation carriers. Disease specific 30 year survival for ovarian cancer was 71.5%, and for all hereditary non-polyposis colon cancer (HNPCC)/Lynch syndrome related cancers including ovarian cancer it was 47.3%. Conclusions: In the series examined, infiltrating ovarian cancer in Lynch syndrome had a better prognosis than infiltrating ovarian cancer in BRCA1/2 mutation carriers or in the general population. Lifetime risk of ovarian cancer of about 10% and a risk of dying of ovarian cancer of 20% gave a lifetime risk of dying of ovarian cancer of about 2% in female MMR mutation carriers.
AB - Background: Women with a germline mutation in one of the MMR genes MLH1, MSH2 or MSH6 reportedly have 4e12% lifetime risk of ovarian cancer, but there is limited knowledge on survival. Prophylactic bilateral salpingooophorectomy (PBSO) has been suggested for preventing this condition. Aim: The purpose of this retrospective multicentre study was to describe survival in carriers of pathogenic mutations in one of the MMR genes, and who had contracted ovarian cancer. Methods: Women who had ovarian cancer, and who tested positive for or were obligate carriers of an MMR mutation, were included from 11 European centres for hereditary cancer. Most women had not attended for gynaecological screening. Crude and disease specific survival was calculated by the KaplaneMeier algorithm. Results: Among the 144 women included, 81.5% had FIGO stage 1 or 2 at diagnosis. 10 year ovarian cancer specific survival independent of staging was 80.6%, compared to less than 40% that is reported both in population based series and in BRCA mutation carriers. Disease specific 30 year survival for ovarian cancer was 71.5%, and for all hereditary non-polyposis colon cancer (HNPCC)/Lynch syndrome related cancers including ovarian cancer it was 47.3%. Conclusions: In the series examined, infiltrating ovarian cancer in Lynch syndrome had a better prognosis than infiltrating ovarian cancer in BRCA1/2 mutation carriers or in the general population. Lifetime risk of ovarian cancer of about 10% and a risk of dying of ovarian cancer of 20% gave a lifetime risk of dying of ovarian cancer of about 2% in female MMR mutation carriers.
UR - http://www.scopus.com/inward/record.url?scp=77349086189&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77349086189&partnerID=8YFLogxK
U2 - 10.1136/jmg.2009.068130
DO - 10.1136/jmg.2009.068130
M3 - Article
VL - 47
SP - 99
EP - 102
JO - Journal of Medical Genetics
JF - Journal of Medical Genetics
SN - 0022-2593
IS - 2
ER -